|

Cabazitaxel Clinical Trials

7 actively recruiting trials across 6 locations

Also known as: JEVTANA®, Jevtana, RPR-116258A, RPR116258A, TXD258 +3 more

Pipeline

Phase 1: 1Phase 2: 2Phase 3: 3Phase 1/2: 1

Top Sponsors

  • Amgen2
  • SWOG Cancer Research Network1
  • Merck Sharp & Dohme LLC1
  • Janssen Research & Development, LLC1
  • Fundacion Oncosur1

Indications

  • Cancer7
  • Castration-Resistant Prostate Carcinoma2
  • Metastatic Castration-resistant Prostate Cancer2
  • Stage IVB Prostate Cancer AJCC v82
  • Metastatic Hormone-sensitive Prostate Cancer1

Other1 trial

Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)
Phase 2

Birmingham, Alabama1 trial

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

University of Alabama at Birmingham

Phase 3

Tucson, Arizona1 trial

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Banner University Medical Center - Tucson

Phase 2

Fayetteville, Arkansas1 trial

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Highlands Oncology Group - Fayetteville

Phase 3

Duarte, California1 trial

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

City of Hope National Medical Center

Phase 3

La Jolla, California1 trial

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

UCSD Moores Cancer Center ( Site 0039)

Phase 1/2

Sarasota, Florida1 trial

A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer

Florida Cancer Specialists

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.